Table 1 Primary features of the included studies
Study; Location | Sample size (n) | Gender distribution | Age of dogs (months) | Sample type; sample amount collected | Sample collection time; collection duration | Total protein concentration measurement |
|---|---|---|---|---|---|---|
Healthy dogs-associated proteomics studies | ||||||
(de Sousa-Pereira et al. [52]); Portugal | Healthy = 1 | 1 M/0F | NR | UWS; NR | NR; 4 min | Bradford assay |
(Lucena et al. [46]); Portugal | Healthy = 53 | 29 M/24F | 6–132 | UWS; NR SWS; NR | 3:30–6:30 p.m.; 2 min | Bradford assay |
(Pasha et al. [51]); UK | Healthy = 16 | 8 M/8F | 12–96 | UWS; NR | 8:00 a.m.; 30 s | BCA |
(Sanguansermsri et al. [49]); Thailand | Healthy = 7 | NR | 12–36 | UWS; NR | NR | Bradford assay |
(Torres et al. [50]); USA | Healthy = 36 | 16 M/20F | 4–148 | UWS; NR | NR; 1 min | BCA |
(M. Grant et al. [48]); UK | Healthy = 10 | 3 M/7F | 30–78 | UWS & AEP; NR | 8:00 a.m.; 30 s | BCA |
Study | MS-based approach used | Peptide labeling approach | Protein verification approach | Additional approaches | FDR threshold | Proteins identified (significant/abundant) |
(de Sousa-Pereira et al. [52]) | LC-MS/MS | Label-free | SDS-PAGE | LC-MS/MS | 5% | 244 (12) |
(Lucena et al. [46]) | MALDI-TOF-MS | Label-free | SDS-PAGE 2D-PAGE | MALDI-TOF/TOF-MS | NR | 16 (5) |
(Pasha et al. [51]) | LC-MS/MS | TMT | NR | SDS-PAGE | 1% | 72 (9) |
(Sanguansermsri et al. [49]) | LC-MS/MS | Label-free | LC-MS/MS | SDS-PAGE | NR | 2532 (44) |
(Torres et al. [50]) | LC-MS/MS | Label-free | Scaffold software | SDS-PAGE | ≤ 1% | 2491 (10) |
(M. Grant et al. [48]) | LC-MS/MS | TMT | NR | NR | 1% | 96 (5) |
Oral diseases-associated proteomics studies | ||||||
Study; Location | Study groups; sample size | Gender distribution | Age of dogs (months) | Sample type; sample amount collected | Sample collection time; collection duration | Total protein concentration measurement |
(Davis et al. [18]); UK | Mild G; Moderate G; Mild P (Total: 52) | 24 M/28F | 16–83 | GCF; NR | NR; 30 s | NR |
(Pisamai et al. [17]); Thailand | EOM = 7; LOM = 8; OSCC = 7; BOT = 8; Healthy = 8 | NR | 12–192 | NR | NR | Lowry assay |
(Ploypetch et al. [19]); Thailand | EOM = 5; LOM = 24; OSCC = 10; BOT = 11; P = 5; Healthy = 10 | NR | 84–168 | UWS; 500–1000 µL | NR; 5–10 min | Lowry assay |
(Bringel et al. [23]); Canada | Healthy = 8; Calculus = 12 | 7 M/13F | 3–108 | SWS; 100–1000 µL | NR; 5–10 min | µBCA |
(Ploypetch et al. [20]); Thailand | EOM = 5; LOM = 24; OSCC = 10; BOT = 11; P = 5; Healthy = 10 | 36 M/26F | 24–180 | UWS; 500–1000 µL | NR; 5–10 min | Lowry assay |
(Ploypetch et al. [21]); Thailand | OM = 9 | 4 M/5F | 91–157 | UWS; NR | NR | Lowry assay |
(Ploypetch et al. [22]); Thailand | EOM = 5; LOM = 28; LOSCC = 10; BOT = 12; CP = 5; Healthy = 7 | 44 M/23F | 84–168 | Serum; 500 µL | NR | Lowry method |
Study | MS-based approach used | Peptide labeling approach | Protein verification approach | Additional approaches | FDR threshold | Proteins identified (Significant/abundant) |
(Davis et al. [18]) | LC-MS/MS | iTRAQ | ELISA | NR | 1% | 406 (32) |
(Pisamai et al. [17]) | MALDI-TOF-MS coupled with LC-MS/MS | Label-free | LC-MS/MS | SDS-PAGE | NR | 1572 (22) |
(Ploypetch et al. [19]) | MALDI-TOF-MS coupled with LC-MS/MS | Label-free | Western blot | Western blot | NR | 18 |
(Bringel et al. [23]) | LC-MS/MS | Label-free | NR | NR | 1% | 658 (34) |
(Ploypetch et al. [20]) | LC-MS/MS | Label-free | Western blot | Western blot | NR | 3726 (27) |
(Ploypetch et al. [21]) | LC-MS/MS | Label-free | Western blot | Western blot | NR | 74 (1) |
(Ploypetch et al. [22]) | MALDI-TOF-MS coupled with LC-MS/MS | Label-free | NR | NR | NR | 16 (4) |